임상시험 센트럴 랩 서비스 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 페이즈별, 서비스별, 적응증별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Clinical Trial Central Laboratory Services Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Service, By Indication, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,830,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,315,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,283,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

임상시험 센트럴 랩 서비스 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 임상시험 센트럴 랩 서비스 시장 규모는 2030년까지 69억 7,000만 달러에 이를 전망이며, 2025-2030년 연평균 복합 성장률(CAGR) 9.8%로 성장할 것으로 예측됩니다.

이 시장을 견인하고 있는 것은 임상시험 증가, 바이오마커 기반 검사에 대한 수요 증가, 규제 요건의 엄격화, 분산형 시험의 채용 확대 등입니다. 또한 AI 주도의 분석, 자동화, 디지털 랩 관리 시스템 등의 기술적 진보에 의해 효율성이 더욱 향상되어 납기가 단축되어 시험 결과 전체가 개선됩니다.

의약품 개발 프로그램 증가 및 연구 개발에 대한 투자 증가로 시장이 급속히 확대되고 있습니다. 제약사와 바이오테크놀로지 기업들은 혁신적인 치료법을 시장에 투입하기 위해 더 많은 임상시험을 실시하고 있어 전문적인 랩 서비스에 대한 수요를 더욱 끌어올리고 있습니다. 바이오마커에 근거하는 검사, 게놈 해석, 약물 동태학 연구는 임상 시험에 불가결한 것이 되고 있어 고도의 랩 능력을 필요로 하고 있습니다. 규제 당국은 의약품 승인에 엄격한 가이드라인을 부과하고 있어 컴플라이언스, 데이터 정확성, 표준화된 검사 절차를 확보하기 위해 집중형 랩 서비스가 필수적입니다.

또한 분산형 임상시험과 가상 임상시험으로의 전환은 업계를 더욱 변화시켜 효율적인 샘플 수집, 실시간 데이터 통합, 원격검사 솔루션의 필요성을 높이고 있습니다. AI 주도 분석, 자동화, 디지털 랩 관리 시스템 등 신기술은 업무 효율을 높이고 시험 일정을 가속화합니다. 게다가 제약 회사, CRO, 센트럴 랩 프로바이더 간의 전략적 제휴는 랩의 네트워크를 강화하고 세계적인 검사 능력을 확대합니다. 개별화 의료와 정밀 치료에 대한 주목의 고조는, 고품질 랩 서비스에 대한 수요를 계속적으로 부추겨, 업계의 현저한 성장을 가속시키고 있습니다.

시장의 주요 기업은 시장에서의 지위를 강화하기 위해 다양한 전략을 채택하고 있습니다. 여기에는 전략적 파트너십, M&A, 세계 배포를 강화하기 위한 실험실 네트워크 확대 등이 포함됩니다. 각 회사는 AI 주도 분석, 자동화, 바이오마커 기반 검사 등 첨단 기술에 투자하여 효율성과 정밀도를 향상시켰습니다. 예를 들어 2025년 2월 LabConnect는 Sapio Sciences와 파트너십 계약을 체결하고 검사실 정보 관리 시스템(LIMS)을 도입했습니다. 이 제휴는 복잡한 연구 워크플로우를 더욱 디지털화하고 LabConnect 업무의 샘플 추적을 합리화하며 데이터 관리를 강화하는 것을 목적으로 합니다.

임상시험 센트럴 랩 서비스 시장 보고서 하이라이트

• 서비스별로는 유전체 및 분자 검사의 진보로 바이오마커 검사 서비스가 시장을 석권했습니다. 규제 당국도 바이오마커에 기반한 의약품 승인을 장려하고 있어 시장 확대에 더욱 박차를 가하고 있습니다.
• 페이즈별로는 대량의 샘플과 광범위한 검사 요건에 의해 페이즈 III가 2024년에 최대 시장 점유율을 차지했습니다. 후기 임상시험의 증가와 규제당국의 의무화가 중앙검사실 서비스의 수요를 더욱 끌어올리고 있습니다.
• 적응증별로는 암 이환율의 상승과 신규 치료법의 임상시험 증가에 의해 2024년에 냉동이 최대 시장 점유율을 차지했습니다. 개별화 의료와 바이오 마커에 근거한 진단에 대한 주목의 고조가, 전문적인 랩 검사의 수요를 높이고 있습니다.
• 최종 용도별로는 제약 및 바이오 제약 기업이, 그 높은 연구 개발 투자와 광범위한 임상시험 파이프라인에 의해 2024년에 최대 시장 점유율을 차지했습니다. 전문적 검사, 바이오마커 분석, 정밀의료에 대한 수요 증가는 센트럴 랩에 대한 의존을 더욱 강화하고 있습니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 시장의 변수, 동향 및 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련 및 보조 시장 전망
• 시장 동향 및 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 기술의 진보
  • AI 및 디지털 기술의 통합
• 가격 모델 분석
• 임상시험 건수 분석(2024년)
  • 임상시험 총수 : 지역별(2024년)
  • 임상시험 총수 : 페이즈별(2024년)
  • 임상시험 총수 : 연구 디자인별(2024년)
  • 임상시험 총수 : 주요 치료 영역별(2024년)
• 업계 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 임상시험 센트럴 랩 서비스 시장 : 서비스별 추정 및 동향 분석

• 부문 대시보드
• 임상시험 센트럴 랩 서비스 시장 : 서비스별 변동 분석
• 임상시험 센트럴 랩 서비스 규모 및 동향 분석 : 서비스별(2018-2030년)
• 바이오마커 검사 서비스
• 미생물학 서비스
• 해부병리학 및 조직학
• 약동학 및 약역학(PK/PD)
• 유전체 및 분자 검사
• 샘플 수집 및 처리
• 물류 및 샘플 관리
• 데이터 관리 및 보고서
• 기타

제5장 임상시험 센트럴 랩 서비스 시장 : 위상별 추정 및 동향 분석

• 부문 대시보드
• 임상시험 센트럴 랩 서비스 시장 : 위상 변동 분석
• 임상시험 센트럴 랩 서비스 규모 및 동향 분석 : 페이즈별(2018-2030년)
• 페이즈 I
• 페이즈 II
• 페이즈 III
• 페이즈 IV

제6장 임상시험 센트럴 랩 서비스 시장 : 적응증별 추정 및 동향 분석

• 부문 대시보드
• 임상시험 센트럴 랩 서비스 시장 : 적응증별 변동 분석
• 임상시험 센트럴 랩 서비스 규모 및 동향 분석 : 적응증별(2018-2030년)
• 종양학
• 심장병학
• 신경학
• 감염증
• 면역학과자가면역질환
• 기타

제7장 임상시험 센트럴 랩 서비스 시장 : 최종 용도별 추정 및 동향 분석

• 부문 대시보드
• 임상시험 센트럴 랩 서비스 시장 : 최종 용도별 변동 분석
• 임상시험 센트럴 랩 서비스 규모 및 동향 분석 : 최종 용도별(2018-2030년)
• 제약 및 바이오테크놀러지 기업
• 수탁연구기관
• 기타

제8장 임상시험 센트럴 랩 서비스 시장 : 지역별 추정 및 동향 분석

• 지역 대시보드
• 시장 규모, 예측 및 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 기업 분류
• 기업 시장 포지셔닝 분석(2024년)
• 기업 프로파일
  • Labcorp
  • ICON plc
  • Eurofins Scientific
  • Thermo Fisher Scientific Inc.
  • Medpace
  • Q2 Solutions
  • Syneos Health
  • Charles River Laboratories
  • SGS
  • LabConnect

AJY

영문 목차

영문목차

Clinical Trial Central Laboratory Services Market Growth & Trends:

The global clinical trial central laboratory services market size is expected to reach USD 6.97 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing number of clinical trials, rising demand for biomarker-based testing, stringent regulatory requirements, and growing adoption of decentralized trials. Moreover, technological advancements such as AI-driven analytics, automation, and digital lab management systems further enhance efficiency, reduce turnaround times, and improve overall trial outcomes.

The market is expanding rapidly due to the increasing number of drug development programs and growing investments in research and development. Pharmaceutical and biotechnology companies are conducting more clinical trials to bring innovative therapies to market, further driving the demand for specialized laboratory services. Biomarker-based testing, genomic analysis, and pharmacokinetics studies are becoming essential for clinical trials, requiring advanced lab capabilities. Regulatory authorities are imposing stringent guidelines for drug approval, making centralized laboratory services critical for ensuring compliance, data accuracy, and standardized testing procedures.

Furthermore, the shift toward decentralized and virtual trials further transforms the industry, increasing the need for efficient sample collection, real-time data integration, and remote testing solutions. Emerging technologies such as AI-driven analytics, automation, and digital lab management systems enhance operational efficiency and accelerate trial timelines. Moreover, strategic collaborations between pharmaceutical companies, CROs, and central lab providers strengthen laboratory networks and expand global testing capabilities. The growing focus on personalized medicine and precision therapies continues to fuel demand for high-quality laboratory services, accelerating the industry's significant growth.

Key market players are adopting various strategies to strengthen their market position. These include strategic partnerships, mergers and acquisitions, and expanding laboratory networks to enhance global reach. Companies also invest in advanced technologies such as AI-driven analytics, automation, and biomarker-based testing to improve efficiency and accuracy. For instance, in February 2025, LabConnect entered into a partnership agreement with Sapio Sciences to implement a Laboratory Information Management System (LIMS). This collaboration aims to further digitally transform complex research workflows, streamlining sample tracking and enhancing data management within LabConnect's operations.

Clinical Trial Central Laboratory Services Market Report Highlights:

• Based on service, biomarker testing services dominated the market due to genomic and molecular testing advancements. Regulatory agencies are also encouraging biomarker-based drug approvals, further fueling the market expansion
• Based on the phase, Phase III held the largest market share in 2024 due to the high volume of samples and extensive testing requirements. The growing number of late-stage trials and regulatory mandates further drive demand for central lab services
• Based on Indication, frozen held the largest market share in 2024 due to the rising prevalence of cancer and increasing clinical trials for novel therapies. The growing focus on personalized medicine and biomarker-based diagnostics has amplified the demand for specialized laboratory testing
• Based on end use, pharmaceutical & biopharmaceutical companies held the largest market share in 2024 due to their high R&D investments and extensive clinical trial pipelines. The increasing demand for specialized testing, biomarker analysis, and precision medicine further strengthened their reliance on central labs

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Technological Advancements
  • 3.4.1. Integration of AI and Digital Technologies
• 3.5. Pricing Model Analysis
• 3.6. Clinical Trials Volume Analysis, 2024
  • 3.6.1. Total Number of Clinical Trials, by Region (2024)
  • 3.6.2. Total Number of Clinical Trials, by Phase (2024)
  • 3.6.3. Total Number of Clinical Trials, by Study Design (2024)
  • 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
• 3.7. Industry Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL Analysis
  • 3.7.3. COVID-19 Impact Analysis

Chapter 4. Clinical Trial Central Laboratory Services Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Clinical Trial Central Laboratory Services Market; Service Movement Analysis
• 4.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Biomarker Testing Services
  • 4.4.1. Biomarker testing services market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Microbiology Services
  • 4.5.1. Microbiology services market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Anatomic Pathology/Histology
  • 4.6.1. Anatomic pathology/histology market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Pharmacokinetics/Pharmacodynamics (PK/PD)
  • 4.7.1. Pharmacokinetics/Pharmacodynamics (PK/PD) market estimates and forecasts 2018 - 2030 (USD Million)
• 4.8. Genomic and Molecular Testing
  • 4.8.1. Genomic and molecular testing market estimates and forecasts 2018 - 2030 (USD Million)
• 4.9. Sample Collection and Processing
  • 4.9.1. Sample collection and processing market estimates and forecasts 2018 - 2030 (USD Million)
• 4.10. Logistics & Sample Management
  • 4.10.1. Logistics & sample management market estimates and forecasts 2018 - 2030 (USD Million)
• 4.11. Data Management & Reporting
  • 4.11.1. Data management & reporting market estimates and forecasts 2018 - 2030 (USD Million)
• 4.12. Others
  • 4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Clinical Trial Central Laboratory Services Market: Phase Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Clinical Trial Central Laboratory Services Market; Phase Movement Analysis
• 5.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
• 5.4. Phase I
  • 5.4.1. Phase I market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Phase II
  • 5.5.1. Phase II market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Phase III
  • 5.6.1. Phase III market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Phase IV
  • 5.7.1. Phase IV market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Clinical Trial Central Laboratory Services Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Clinical Trial Central Laboratory Services Market; Indication Movement Analysis
• 6.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Cardiology
  • 6.5.1. Cardiology market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Neurology
  • 6.6.1. Neurology market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Infectious Diseases
  • 6.7.1. Infectious Diseases market estimates and forecasts 2018 - 2030 (USD Million)
• 6.8. Immunology & Autoimmune Diseases
  • 6.8.1. Immunology & autoimmune diseases market estimates and forecasts 2018 - 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Clinical Trial Central Laboratory Services Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Clinical Trial Central Laboratory Services Market; End Use Movement Analysis
• 7.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Pharmaceutical & Biotechnology Companies market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Contract Research Organizations
  • 7.5.1. Contract Research Organizations market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Clinical Trial Central Laboratory Services Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. North America clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Germany clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. UK clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. South Korea clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Australia clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Thailand clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Position Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Labcorp
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Service benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. ICON plc
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Service benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Eurofins Scientific
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Service benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Thermo Fisher Scientific Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Service benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Medpace
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Service benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Q2 Solutions
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Service benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Syneos Health
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Service benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Charles River Laboratories
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Service benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. SGS
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Service benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. LabConnect
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Service benchmarking
    • 9.3.10.4. Strategic initiatives

관련자료